

Centers for Disease Control

Subject: Pulmonary Function Testing Course Approval and Reapproval Criteria—New

Respondents: State or local governments; businesses, small businesses, or other for profit organizations; Federal agencies or employees; not for profit institutions
OMB Desk Officer: Fay S. Iudicello

National Institutes of Health

Subject: Physical Examination and Testing of the Framingham Offspring (Cycle 3) (0925-0098)—New

Respondents: Individuals or households
Subject: A Next-of-Kin Case—Control Study of Esophageal Cancer Among South Carolina Coastal Males—New
Respondents: Individuals or households
OMB Desk Officer: Fay S. Iudicello

Office of the Secretary

Subject: Clearinghouse Questionnaire—New

Respondents: HMS clearinghouse
OMB Desk Officer: Milo Sunderhauf

Social Security Administration

Subject: Application for Benefits Under the Norway—U.S. International Social Security Agreement (SSA-796 (11-83))—New

Respondents: Workers eligible for Social Security benefits from U.S. and/or Norway

Subject: Request for a Certificate of Coverage—New

Respondents: Workers eligible for Social Security Coverage by U.S. and foreign countries

Subject: Quarterly Work Incentive (WIN) Demonstration Program Report (0960-0254) (SSA-4769)—Revision

Respondents: State agencies administering WIN demonstration projects

OMB Desk Officer: Milo Sunderhauf

Health Care Financing Administration

Subject: Freestanding Federally Funded Health Center Cost Report (0938-0235)—Extension/No Change

Respondents: 127 freestanding Federally funded health centers

Subject: Information Collection Requirements in Regulation Sections 405.1627 and 405.1629, Physician Certification and Recertification (Prospective Payment Regulation BERC-263) (0938-0306)—Extension/No Change

Respondents: Physicians accepting Medicare patients (outlier cases only)

OMB Desk Officer: Fay S. Iudicello

Copies of the above information collection clearance packages can be obtained by calling the HHS Reports Clearance Officer on 202-245-6511.

Written comments and recommendations for the proposed information collections should be sent directly to the appropriate OMB Desk Officer designated above at the following address: OMB Reports Management Branch, New Executive Officer Building, Room 3206, Washington D.C. 20503; ATTN: (name of OMB Desk Officer).

Dated: November 15, 1983.

Robert F. Sormier,
Deputy Assistant Secretary for Management Analysis and Systems.

[FR Doc. 83-31078 Filed 11-17-83; 8:45 am]

BILLING CODE 4150-04-M

Food and Drug Administration**Consumer Participation; Open Meetings**

AGENCY: Food and Drug Administration.
ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is announcing the following consumer exchange meetings:

Minneapolis District Office, chaired by John Feldman, District Director. The topic to be discussed is Drug Use and the Elderly.

Date: Tuesday, November 29, 1983, 10 a.m.
 Address: Minnesota Church Center, 122 West Franklin Ave., Minneapolis, MN 55404.
 For Further Information Contact: Therese A. Bowker, Consumer Affairs Officer, Food and Drug Administration, 240 Hennepin Ave., Minneapolis, MN 55401, 612-725-2121.

Los Angeles District Office, chaired by Abraham I. Kleks, District Director. The topic to be discussed is Drug Use and the Elderly.
 Date: Tuesday, November 29, 1983, 1 p.m.
 Address: Cooperative Extension Auditorium, 4341 East Broadway, Phoenix, AZ 85040.

For Further Information Contact: Irene Gomez Caro, Consumer Affairs Officer, Food and Drug Administration, 1521 West Pico Blvd., Los Angeles, CA 90015, 213-688-4395.

Dallas District Office, chaired by James Anderson, District Director. The topic to be discussed is Drug Use and the Elderly.
 Date: Tuesday, November 29, 1983, 7 p.m.
 Address: 509 North Bell Ave., Denton, TX 76201.

For Further Information Contact: Don Aird, Consumer Affairs Officer, Food and Drug Administration, 1200 Main Tower Bldg., Dallas, TX 75202, 214-767-5433.

Brooklyn District Office, chaired by George J. Gerstenberg, District Director. The topic to be discussed is Drug Use and the Elderly.
 Date: Thursday, December 1, 1983, 1:30 p.m.
 Address: 26 Federal Plaza, Rm. 305A, New York, NY 10278.

For Further Information Contact: Herman B. Janiger, Consumer Affairs Officer, Food and Drug Administration, 850 Third Ave., Brooklyn, NY 11232, 211-965-5043.

Detroit District Office, chaired by Alan L. Hoeting, District Director. The topics to be

discussed are Drug Use and the Elderly; and Aspartame Update.

Date: Monday, December 5, 1983, 1 to 3 p.m.

Address: City-County Administration Bldg., Rm. 24, Evansville, IN 47708.

For Further Information Contact: Lilyan M. Goossens, Consumer Affairs Officer, Food and Drug Administration, 575 North Pennsylvania St., Rm. 683, Indianapolis, IN 46204, 317-259-6500.

SUPPLEMENTARY INFORMATION: The purpose of these meetings is to encourage dialogue between consumers and FDA officials, to identify and set priorities for current and future health concerns, to enhance relationships between local consumers and FDA's District Offices, and to contribute to the agency's policymaking decisions on vital issues.

Dated: November 14, 1983.

William F. Randolph,
Acting Associate Commissioner for Regulatory Affairs.

[FR Doc. 83-31107 Filed 11-17-83; 8:45 am]

BILLING CODE 4160-07-M

[Docket No. 83A-8339]

Enforcement Action Under the New Drug Provisions of the Federal Food, Drug, and Cosmetic Act; Certain OTC Drug Products; Advisory Opinion

AGENCY: Food and Drug Administration.
ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is announcing its advisory opinion which states that the agency is prepared to take immediate enforcement action under the new drug provisions of the Federal Food, Drug, and Cosmetic Act (the act) against certain over-the-counter (OTC) drug products (1) labeled as stimulants and containing anything other than caffeine as the active ingredient and (2) labeled for any purpose and containing as their sole active ingredients any of the following combinations, including their salts, (a) caffeine in combination with ephedrine or pseudoephedrine, (b) phenylpropanolamine in combination with ephedrine or pseudoephedrine, (c) phenylpropanolamine in combination with caffeine. This action is necessary because of the widespread abuse of these products intended to produce effects similar to those produced by substances subject to the Controlled Substances Act (CSA). The intended effect of this action is to eliminate misuse and abuse of these products.

EFFECTIVE DATE: November 18, 1983.

FOR FURTHER INFORMATION CONTACT: Edwin V. Dutra, Jr., Nations' Center for